Cyclosporine in thoracic organ transplantation

Transplantation Proceedings

Volumn 36, Issue 2 SUPPL., 2004, Pages

  Banner, N R ^a   Yacoub, M H ^b  

^a HAREFIELD HOSPITAL   (United Kingdom)

^b Harefield Research Foundation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ALLOIMMUNITY; ARTICLE; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GRAFT REJECTION; HEART LUNG TRANSPLANTATION; HUMAN; NEPHROTOXICITY; PRIORITY JOURNAL; PROPHYLAXIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE;

CALCINEURIN; CYCLOSPORINE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MODELS, BIOLOGICAL; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 1642290876     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.031     Document Type: Article

References (54)

1. Merrill J.P., Murray J.E., Harrison J.H., et al. Successful homotransplantation of the kidney between identical twins. JAMA. 160:1956;277.
2. Calne R.Y. The rejection of renal homografts: inhibition in dogs by 6-mercaptopurine. Lancet. 1:1960;417.
3. Murray J.E., Merill J.P., Harrison J.H., et al. Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med. 268:1963;1315.
4. Barnard C.N. The operation. A human cardiac transplant an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 41:1967;1271.
5. Caves P.K., Stinson E.B., Billingham M.E., et al. Serial transvenous biopsy of the transplanted human heart. Improved management of acute rejection episodes. Lancet. 1:1974;821.
6. Bieber C.P., Griepp R.B., Oyer P.E., et al. Use of rabbit antithymocyte globulin in cardiac transplantation. Relationship of serum clearance rates to clinical outcome. Transplantation. 22:1976;478.
7. Leaf A: The MGH. trustees say no to heart transplants. N Engl J Med. 303:1980;998.
8. Kay J.E. Inhibitory effects of cyclosporin A on lymphocyte activation. Thomson A.W. Cyclosporin. 1989;1 Kluwer Academic, Dordrecht.
9. Borel J.F., Feurer C., Gubler H.U., et al. Biological effects of cyclosporin A a new antilymphocytic agent. Agents Actions. 6:1976;468.
10. Calne R.Y., White D.J., Thiru S., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323.
11. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet. 2:1983;986.
12. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med. 309:1983;809.
13. Oyer P.E., Stinson E.B., Jamieson S.W., et al. Cyclosporine in cardiac transplantation a 2 1/2 year follow up. Transplant Proc. 15:(suppl 1):1983;2546.
14. Emery R.W., Cork R., Christensen R., et al. Cardiac transplant patient at one year. Cyclosporine vs conventional immunosuppression. Chest. 90:1986;29.
15. Cooper D.K. Transplantation of the heart and both lungs. I. Historical review. Thorax. 24:1969;383.
16. Wildevuur C.R., Benfield J.R. A review of 23 human lung transplantations by 20 surgeons. Ann Thorac Surg. 9:1970;489.
17. Reitz B.A., Wallwork J.L., Hunt S.A., et al. Heart-lung transplantation successful therapy for patients with pulmonary vascular disease. N Engl J Med. 306:1982;557.
18. Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 314:1986;1140.
19. Taylor D.O., Edwards L.B., Mohacsi P.J., et al. The registry of the International Society for Heart and Lung Transplantation twentieth official adult heart transplant report - 2003. J Heart Lung Transplant. 22:2003;616.
20. Banner NR, Lyster H, Yacoub MH: Clinical immunosuppression using the calcineurin-inhibitors ciclosporin and tacrolimus. In Cohen P, (ed), Handbook of Experimental Pharmacology. Berlin: Springer-Verlag (in press).
21. Rose M.L., Hutchinson I.V. Immunological mechanisms of graft injury. Banner N.R., Polak J.M., Yacoub M.H. Lung transplantation. 2003;185 Cambridge University Press, Cambridge UK.
22. Kahan B.D. Cyclosporine. N Engl J Med. 321:1989;1725.
23. Myers B.D., Ross J., Newton L., et al. Cyclosporine-associated chronic nephropathy. N Engl J Med. 311:1984;699.
24. Oellerich M., Armstrong V.W., Kahan B., et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit. 17:1995;642.
25. Goldstein D.J., Zuech N., Sehgal V., et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation incidence and progression. Transplantation. 63:1997;664.
26. Myers B.D., Sibley R., Newton L., et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 33:1988;590.
27. Banner N.R. Cytomegalovirus infection. Banner N.R., Polak J.M., Yacoub M.H. Lung Transplantation. 2003;261 Cambridge University Press, Cambridge UK.
28. Cohen J.I. Epstein-Barr virus infection. N Engl J Med. 343:2000;481.
29. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G., et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 323:1990;1723.
30. Opelz G., Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 342:1993;1514.
31. Li Y., Li X.C., Zheng X.X., et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 5:1999;1298.
32. Lechler R.I., Ng W.F., Camara N.O. Infectious tolerance? Mechanisms and implications. Transplantation. 72:(suppl 8):2001;S29.
33. Banner N.R. Coronary arterial disease in the cardiac allograft. Rose M.L. Transplant-associated coronary artery disease. 2001;1 Landes Bioscience, Georgetown, Texas.
34. Hertz M.I. Chronic lung allograft dysfunction. Banner N.R., Polak J.M., Yacoub M.H. Lung Transplantation. 2003;243 Cambridge University Press, Cambridge.
35. Banner N.R., Lyster H. Pharmacological Immunosuppression. Banner N.R., Polak J.M., Yacoub M.H. Lung Transplantation. 2003;205 Cambridge University Press, Cambridge.
36. Yacoub M.H., Alivizatos P., Khaghani A., et al. The use of cyclosporine, azathioprine and antithymocyte globulin with or without low dose steroids for immunosuppression of cardiac transplant patients. Transplant Proc. 17:1985;221.
37. Banner N.R., Fitzgerald M., Khaghani A., et al. Cardiac transplantation at, Harefield Hospital. Terasaki P.I. Clinical Transplants 1987. 1987;17 University of California, Los Angeles.
38. Gao S.Z., Schroeder J.S., Alderman E.L., et al. Prevalence of accelerated coronary artery disease in heart transplant survivors. Comparison of cyclosporine and azathioprine regimens. Circulation. 80:1989;III100.
39. Keogh A., Macdonald P., Mundy J., et al. Five-year follow-up of a randomized double-drug versus triple-drug therapy immunosuppressive trial after heart transplantation. J Heart Lung Transplant. 11:1992;550.
40. Kobashigawa J., Miller L., Renlund D., et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 66:1998;507.
41. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621.
42. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 344:1994;423.
43. U.S. Multicenter FK506 Liver Study. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. The U.S. Multicenter FK506 Liver Study Group. N Engl J Med. 331:1994;1110.
44. Taylor D.O., Barr M.L., Radovancevic B., et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant. 18:1999;336.
45. Mentzer R.M. Jr, Jahania M.S., Lasley R.D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation. 65:1998;109.
46. Meiser B.M., Uberfuhr P., Fuchs A., et al. Tacrolimus a superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant. 16:1997;795.
47. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 54:1993;205.
48. Best N.G., Trull A.K., Tan K.K., et al. Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation. Br J Clin Pharmacol. 34:1992;513.
49. Mueller E.A., Kovarik J.M., van Bree J.B., et al. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm Res. 11:1994;301.
50. Eisen H.J., Hobbs R.E., Davis S.F., et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine-results at 24 months after transplantation. Transplantation. 71:2001;70.
51. Levy G.A. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 15:2001;279.
52. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 349:2003;847.
53. Johnson R.W., Kreis H., Oberbauer R., et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation. 72:2001;777.
54. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 67:1999;1036.